Acetyl Hexapeptide-3

A synthetic hexapeptide that mimics the N-terminal end of SNAP-25, a protein essential for SNARE complex formation and neurotransmitter release. By inhibiting this complex in a mechanism analogous to botulinum toxin, Argireline reduces the intensity of facial muscle contractions that cause expression lines — earning it the nickname 'topical Botox.'

• Competes with SNAP-25 for incorporation into the SNARE complex
• Reduces vesicle docking and acetylcholine release at neuromuscular junctions
• Attenuates muscle contraction intensity without full paralysis
• Dose-dependent inhibition of catecholamine release demonstrated in vitro

• Concurrent botulinum toxin injections in the same area (compounding effect unclear)
• Known allergy to peptide ingredients
• Application on broken or severely inflamed skin

Store at room temperature (15–25°C (59–77°F)) in a cool, dry place away from sunlight. Concentrated solutions: keep at 2–8°C (36–46°F). Stable for 12-18 months in properly formulated products.

Developed by Lipotec (now part of Lubrizol), Argireline was introduced in 2002 and quickly became a bestselling cosmetic peptide. In vitro studies showed 41% inhibition of SNARE complex formation at 0.05 mM. A 30-day clinical study demonstrated a 30% reduction in wrinkle depth around the eyes. While less potent than injectable botulinum toxin, its non-invasive nature and good safety profile have made it one of the most commercially successful cosmetic peptides globally.